AcelRx reports revenue of $408,000 for third quarter 2011 AcelRx Pharmaceuticals, Inc. , , a specialty pharmaceutical company focused on the advancement and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today for the third quarter and nine months finished September 30 reported financial results, 2011. Net reduction for the third quarter of 2011 was $5.8 million, or $0.30 per share, weighed against a net lack of $3.6 million, or $5.38 per share, for the third quarter of 2010. Through the third quarter of 2011, AcelRx acknowledged revenue of $408,000 caused by reimbursement for work completed under a research grant from the united states Army Medical Analysis and Material Control, or USAMRMC, for advancement of its ARX-04 product candidate.9 million, weighed against $1.september 30 5 million for the three months ended, 2010.september 30 9 million for the quarter ended, 2011, weighed against $1.1 million for the quarter ended September 30, 2010.‘Based on how rapidly HIV changes, we assumed that we could find out something by concentrating on Apobec3G,’ she stated. Sawyer and colleagues propose that Apobec3G’s primary enemy is definitely a family group of virus-like invaders of the genome known as retrotransposons. Known as mobile genetic elements, these snippets of DNA are usually relics of historic viral infections that insert themselves into many locations in the genome, regardless of whether they could disrupt the genes that inhabit those locations.